Shire PLC (LON:SHP)‘s stock had its “buy” rating reissued by stock analysts at Berenberg Bank in a note issued to investors on Thursday, May 11th. They presently have a GBX 5,900 ($76.24) price objective on the biopharmaceutical company’s stock. Berenberg Bank’s target price would indicate a potential upside of 30.00% from the company’s current price.
A number of other analysts have also weighed in on SHP. BNP Paribas restated an “outperform” rating and issued a GBX 5,900 ($76.24) target price on shares of Shire PLC in a research note on Monday, April 3rd. Shore Capital restated a “buy” rating on shares of Shire PLC in a report on Monday, April 24th. Jefferies Group LLC restated a “buy” rating and set a GBX 6,600 ($85.28) target price on shares of Shire PLC in a report on Friday, February 17th. Liberum Capital reiterated a “buy” rating and set a GBX 5,500 ($71.07) price objective on shares of Shire PLC in a report on Friday, February 17th. Finally, HSBC Holdings plc lifted their target price on Shire PLC from GBX 4,500 ($58.15) to GBX 4,550 ($58.79) and gave the company a “hold” rating in a research report on Tuesday, February 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of GBX 6,102.27 ($78.85).
Shire PLC (LON:SHP) traded down 0.34% during midday trading on Thursday, reaching GBX 4538.50. 2,088,685 shares of the company traded hands. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00. The company’s market cap is GBX 41.03 billion. The company has a 50-day moving average price of GBX 4,631.67 and a 200-day moving average price of GBX 4,646.85.
TRADEMARK VIOLATION NOTICE: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.com-unik.info/2017/06/05/shire-plc-shp-earns-buy-rating-from-berenberg-bank-updated-updated.html.
In related news, insider William Burns purchased 136 shares of the firm’s stock in a transaction dated Friday, March 31st. The stock was bought at an average price of GBX 4,742 ($61.27) per share, with a total value of £6,449.12 ($8,333.27).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
What are top analysts saying about Shire PLC? – Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts’ recommendations for for Shire PLC and related companies.